0
Clinical Investigations in Critical Care |

Outcomes up to 5 Years After Severe, Acute Respiratory Failure*

Allan Garland, MD, FCCP; Neal V. Dawson, MD; Irene Altmann, MD; Charles L. Thomas, AB; Russell S. Phillips, MD; Joel Tsevat, MD, MPH; Norman A. Desbiens, MD; Paul E. Bellamy, MD; William A. Knaus, MD; Alfred F. Connors, Jr, MD, FCCP; for the SUPPORT Investigators
Author and Funding Information

Affiliations: *From the Case Western Reserve University School of Medicine (Drs. Garland, Dawson, and Connors, and Mr. Thomas), Cleveland, OH; The Everett Clinic (Dr. Altmann), Everett, WA; the Harvard Medical School (Dr. Phillips), Boston, MA; the University of Cincinnati Medical Center (Dr. Tsevat), Cincinnati, OH; the University of Tennessee College of Medicine (Dr. Desbiens), Chattanooga, TN; Kaiser Permanente (Dr. Bellamy), Woodland Hills, CA; and the University of Virginia Health Sciences System (Dr. Knaus), Charlottesville, VA.,  The research was performed at the following institutions: MetroHealth Medical Center, Cleveland, OH; Duke University Medical Center, Durham, NC; Beth Israel Hospital, Boston, MA; UCLA Medical Center, Los Angeles, CA; and Marshfield Clinic, Marshfield, WI.

Correspondence to: Allan Garland, MD, FCCP, Division of Pulmonary and Critical Care Medicine, MetroHealth Medical Center, 2500 MetroHealth Dr, Cleveland, OH 44109; e-mail: agarland@metrohealth.org



Chest. 2004;126(6):1897-1904. doi:10.1378/chest.126.6.1897
Text Size: A A A
Published online

Study objective: To use an existing database from a large cohort study with follow-up as long as 5.5 years to assess the extended prognosis of patients who survived their hospitalizations for severe acute respiratory failure (ARF).

Design, setting, and patients: Secondary analysis of an inception cohort of 1,722 patients with ARF requiring mechanical ventilation from five major medical centers who were entered into the prospective Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. The 1,075 patients (62.4%) who survived hospitalization had systematic follow-up of vital status for a median time of 662 days (interquartile range, 327 to 1,049 days; range, 2 to 2,014 days). Interviews performed a median of 5 months after hospital discharge assessed functional capacity and quality of life (QOL). The main outcome measure was survival after hospital discharge. Secondary measures were functional status and QOL. Cox proportional hazard regression identified factors influencing posthospital survival.

Results: The median survival time after hospital discharge for ARF was > 5.3 years. The posthospital survival time was shorter for those with older age, male gender, several preexisting comorbid conditions, worse prehospital functional status, greater acute physiologic derangement, and a do-not-resuscitate order while in the hospital, and for those discharged to a location other than home. Five months after hospital discharge, 48% of survivors needed help with at least one activity of daily living, and 27% rated their QOL as poor or fair. However, most of these impairments were present before respiratory failure occurred.

Conclusions: Extended survival is common among patients with ARF who require mechanical ventilation and who survive hospitalization. Among these patients, only a small fraction of the impairment in activity and QOL can be considered to be a sequela of the respiratory failure or its therapy. These findings are relevant to the care decisions for such critically ill patients.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543